Table 2.

Multivariate analyses

Cohort		FFS			OS
		HR	95% CI	P	HR	95% CI	P
BCCA*	FOXP1 high	1.84	1.10-3.08	.021	2.04	1.08-3.86	.029
	R maintenance	0.89	0.49-1.61	.700	1.53	0.69-3.38	.292
	FLIPI high risk	2.19	1.31-3.66	.003	4.23	2.07-8.61	<.001
GLSG model without FLIPI†	FOXP1 high (no R)	1.15	0.80-1.67	.44	0.68	0.39-1.18	.17
	FOXP1 high (R)	1.95	1.13-3.38	.017	1.82	0.83-4.01	.14
	First-line rituximab (FOXP1 low)	0.25	0.14-0.44	<.001	0.37	0.16-0.83	.016
	First-line rituximab (FOXP1 high)	0.42	0.30-0.60	<.001	0.99	0.58-1.67	.96
	FOXP1:rituximab (interaction term)	1.69	0.98-3.27	.12	2.68	1.02-7.02	.045
GLSG model with FLIPI‡	FOXP1 high (no R)	1.06	0.73-1.54	.76	0.62	0.36-1.08	.092
	FOXP1 high (R)	1.84	1.05-3.24	.035	1.38	0.62-3.08	.43
	First-line rituximab (FOXP1 low)	0.23	0.13-0.42	<.001	0.38	0.17-0.86	.019
	First-line rituximab (FOXP1 high)	0.41	0.28-0.58	<.001	0.85	0.49-1.46	.55
	FOXP1:rituximab (interaction term)	1.74	0.89-3.40	.11	2.23	0.85-5.90	.10
	FLIPI high risk	1.62	1.21-2.17	.0014	2.78	1.74-4.43	<.001

Bold values indicate statistical significance.

R, rituximab.

*n = 138 patients/64 events for FFS, 43 events for OS.

†n = 390 patients/191 events for FFS, n = 395 patients/86 events for OS.

‡n = 381 patients/189 events for FFS, n = 383 patients/84 events for OS.